How to Stack SS-31 + MOTS-C (Exact Dosing Protocol)

Your mitochondria are not just energy factories. They are signaling systems, and the two peptides in this protocol speak entirely different dialects of that language.

To understand why this stack works the way it does, you need the map first. SS-31 is a synthetic peptide that targets something called cardiolipin, which is a specialized fat molecule embedded in the inner mitochondrial membrane. Cardiolipin acts like structural glue that holds the protein complexes of your electron transport chain in the right geometry. When cardiolipin oxidizes and warps with age, those complexes fall apart, electron flow becomes inefficient, and you generate far more reactive oxygen species than you should. SS-31 binds to cardiolipin directly and stabilizes it. That is its entire job.

MOTS-c works at a completely different level. It is a peptide your mitochondria actually make themselves, encoded in the mitochondrial genome, and it functions like a cellular stress signal. When it reaches the nucleus it activates something called the AMPK-FOXO pathway, which is a genetic program your cells run to improve metabolic efficiency, reduce inflammation, and maintain muscle homeostasis. The peptide itself clears your system within hours, but the gene expression it triggers keeps running long after it is gone.

One pathway is structural. One is transcriptional. They do not compete for the same targets, they do not share receptors, and they do not interfere with each other's mechanisms. That is the logic behind combining them.

Now into the dosing, because this is where the data gets specific and the specifics matter.

SS-31 has about a two hour half-life, which means it clears quickly from plasma. But the reason you still run it daily is that the benefit is not about keeping the peptide in circulation. It is about accumulation at the target. SS-31 carries a positive charge that causes it to concentrate roughly five thousand fold at the inner mitochondrial membrane compared to plasma levels. The structural repair to cardiolipin builds over weeks of consistent exposure. You are not medicating daily to maintain drug levels. You are maintaining the conditions for a slow structural process to complete.

The dose question was actually tested in a phase two trial called PROGRESS-HF, which compared four milligrams against forty milligrams in heart failure patients. Forty milligrams showed no advantage over four. The five thousand fold concentration effect explains why. Even low doses are arriving at the membrane in quantities large enough to do the work, so more plasma dose does not translate to more effect. The working range in practice is one to five milligrams per day, with two milligrams being the point where most people get the result without running unnecessary excess.

MOTS-c dosing logic runs in the opposite direction. Because it works through gene expression rather than plasma levels, you do not need it in your system continuously. A study published in Nature Communications confirmed that three times per week maintains all the benefits that daily dosing establishes. The gene program it activates does not need constant retriggering. Monday, Wednesday, Friday at roughly three to five milligrams per injection puts you in the five to fifteen milligram weekly range where the data supports effect.

The combined protocol most people land on is two milligrams of SS-31 daily and ten milligrams of MOTS-c spread across three injections per week. If you are newer to either peptide, starting at half those numbers for the first four weeks gives your system time to respond before you push toward the ceiling. If you are dealing with measurable age-related functional decline, the upper end of five milligrams SS-31 daily and fifteen milligrams MOTS-c weekly is where the clinical and animal data suggest more significant intervention is warranted.

Now, the cycling question, because this is where most of the confusion lives.

The standard recommendation is eight to twelve weeks on followed by four to eight weeks off, and that recommendation is not wrong, but it is also not based on evidence that these peptides require cycling. It is precautionary, and there is an important difference.

SS-31 does not bind a receptor. It binds a lipid. There is no receptor downregulation mechanism, no desensitization, no feedback loop that tells your body to produce less of anything in response to it. The longest continuous human trial ran SS-31 for 168 weeks, which is over three years, in Barth syndrome patients, a mitochondrial cardiomyopathy, and what they observed was not tolerance. They observed progressive improvement across the full duration.

MOTS-c is something your mitochondria synthesize naturally. Its decline with age is part of why mitochondrial function deteriorates. Supplementing it externally does not suppress endogenous production the way exogenous testosterone suppresses the HPG axis, because there is no analogous feedback loop. In animal research, MOTS-c was administered for the remainder of the animals' lives and benefits were sustained without evidence of diminishing returns.

The reason a cycling protocol is still recommended is simpler than most people expect. There are no long-term human studies combining these two peptides at these doses. The 168-week SS-31 trial used forty milligrams daily in a specific disease population. The MOTS-c long-term data is animal data. Cycling is the appropriate conservative posture when the human long-term data does not yet exist, not because the biology suggests a problem.

It is also worth being direct about the combination itself. No published human trial has ever tested SS-31 and MOTS-c together. The rationale for stacking them is built from understanding each mechanism independently and recognizing that those mechanisms do not overlap in any way that would create interference. The closest published evidence is a 2020 study in Aging Cell that combined SS-31 with NMN in aged mice and observed synergistic effects, which supports the logic of combining complementary mitochondrial interventions, but that is not the same as combination data for this specific stack.

The honest version of this protocol is: the individual mechanisms are well characterized, the doses are grounded in human trial data, the biological rationale for combining them is sound, and the long-term combination data in humans does not yet exist.

What the science has actually established is that your mitochondria are failing in two distinct and somewhat independent ways as you age, one structural and one transcriptional, and these two peptides address exactly those two failure modes without stepping on each other's work.

---

References

1. Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a mitochondrial cardiomyopathy. Genetics in Medicine. 2024;267:101133. 168-week continuous SS-31 at 40mg daily with progressive improvement and no tolerance. Source
2. Butler J, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial. Journal of Cardiac Failure. 2020;265:429-437. 4mg vs 40mg comparison: 40mg showed no advantage over 4mg. Source
3. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. 3x/week maintenance dosing preserved all benefits after daily loading. Source
4. Gudiksen A, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent manner. Free Radical Biology and Medicine. 2026;246:682-696. MOTS-C improves mitochondrial quality without increasing content, reduces ROS. Source
5. Whitson JA, et al. SS-31 and NMN: Two paths to improve metabolism and function in aged hearts. Aging Cell. 2020;1910:e13213. Closest published combination data: SS-31 + NMN synergy in aged mice. Source
6. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;213:443-454. Original MOTS-C dosing data: 0.5mg/kg chronic, 5mg/kg acute in mice. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness